Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease
NCT ID: NCT03323476
Last Updated: 2026-01-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
136 participants
INTERVENTIONAL
2018-02-02
2031-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients with ESRD related to AAV will be randomized into 2 arms:
arm 1: discontinuation (or not initiation) of maintenance treatment (Experimental group) arm 2: maintenance (or initiation) of immunosuppressive treatment (Control group).
The main objective of this study is to demonstrate a superiority of immunosuppression discontinuation in ESRD-AAV patients compared to standard maintenance immunosuppressive therapy in terms of severe prejudicial event-free survival at 24 months. The second objectives include the frequency of major and minor relapses, of infectious episodes and leukopenia in both groups and the establishment of a prospective database regarding the outcome of ESRD-AAV patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
NCT03942887
Intravenous Immunoglobulin After Relapse in Vasculitis
NCT00307658
Comparison of ANCA and Anti-GBM Auto-antibodies Removal Kinetics Between Plasma Exchanges and Immunoadsorption in Patients With ANCA-associated Vasculitis or Anti-GBM Disease
NCT03635385
Clinical Relevance of Anti-Neutrophil Cytoplasm Antibody (ANCA)in Hospitalized Patients
NCT01238003
Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis
NCT00987389
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Discontinuation of maintenance treatment
Discontinuation (or not initiation) of Immunosuppressive Therapy
Discontinuation (or not initiation) of Immunosuppressive Therapy
Maintenance of immunosuppressive treatment
Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®
Maintenance (or initiation) of Immunosuppressive Therapy: Imurel®, Mabthera®,Cellcept®, Cortancyl®
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Discontinuation (or not initiation) of Immunosuppressive Therapy
Discontinuation (or not initiation) of Immunosuppressive Therapy
Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®
Maintenance (or initiation) of Immunosuppressive Therapy: Imurel®, Mabthera®,Cellcept®, Cortancyl®
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients affected by a GPA or MPA AAV with a renal injury
* Patients with initial manifestation or relapse of AAV
* Patients with ESRD, defined by a glomerular filtration rate estimated using the MDRD formula ≤15 mL/min or requirement for dialysis for more than 60 days
* Patients with ESRD on native kidney
* Patients who gave written informed consent for participation in the study
* Patients with affiliation to the French social security system
Exclusion Criteria
* Patients with AAV-associated renal involvement (with active inflammatory lesions in kidney biopsy) diagnosed less than three months and receiving induction treatment with cyclophosphamide or rituximab or diagnosed less than 45 days for patients who have receveid only treatment based on steroid infusion without cyclophosphamide or rituximab
* Patients who received maintenance immunosuppressive treatment for more than 6 months during the last 12 months
* Patient with a diagnosis of vasculitis other than GPA or MPA
* Patients with another immunologic systemic disease (Lupus, sarcoidosis…) Patients with active HCV, HBV or HIV infection
* Patients with a history of serious viral infection (CMV, HHV8, etc.) in the 2 months prior to the inclusion, or severe uncontrolled chronic infection (tuberculosis, etc.)
* Patients with uncontrolled cancer or hemopathy
* Kidney transplant patient
* Inability to understand and sign the informed consent
* Pregnant women.
* Women of child-bearing age without effective method of contraception
* Age \< 18 years or \> 90 years.
* Patients under guardianship or trusteeship.
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Departemental Vendee
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Grégoire COUVRAT-DESVERGNES
Role: PRINCIPAL_INVESTIGATOR
CHD Vendée
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Universitaire Amiens
Amiens, , France
CHU Angers
Angers, , France
Centre Hospitalier Angoulême
Angoulême, , France
Centre Hospitalier ARRAS
Arras, , France
Centre Hospitalier Avignon
Avignon, , France
AUB Santé
Avranches, , France
CHRU Besançon
Besançon, , France
Centre Hospitalier Universitaire Bordeaux
Bordeaux, , France
APHP Ambroise Paré
Boulogne-Billancourt, , France
Centre Hospitalier Boulogne sur Mer
Boulogne-sur-Mer, , France
Centre Hospitalier Jacques Coeur
Bourges, , France
Centre Hospitalier Universitaire de Brest
Brest, , France
Centre Hospitalier René Dubois - Pontoise
Cergy-Pontoise, , France
Centre Hospitalier Chartres
Chartres, , France
Centre Hospitalier Universitaire G. Montpied
Clermont-Ferrand, , France
Hopital Louis Pasteur
Colmar, , France
Centre Hospitalier Universitaire de Dijon
Dijon, , France
CHI Eure Seine
Évreux, , France
Centre Hospitalier Universitaire Grenoble
Grenoble, , France
Centre Hospitalier Départemental Vendée
La Roche-sur-Yon, , France
Centre Hospitalier La Rochelle
La Rochelle, , France
Centre ECHO - Le Mans
Le Mans, , France
Centre Hospitalier Le Mans
Le Mans, , France
Centre Hospitalier Emile ROUX
Le Puy-en-Velay, , France
Hôpital Privé La Louvière
Lille, , France
CHRU Lille
Lille, , France
Centre Hospitalier Universitaire Dupuytren
Limoges, , France
AUB Santé - Lorient
Lorient, , France
Centre Hospitalier Lyon Sud
Lyon, , France
Hopital de la Conception - APHM
Marseille, , France
Centre Hospitalier de Mont de Marsan
Mont-de-Marsan, , France
Centre Hospitalier Universitaire Lapeyronie
Montpellier, , France
GHR Mulhouse Sud Alsace
Mulhouse, , France
Centre Hospitalier Universitaire de Nantes
Nantes, , France
Centre Hospitalier Universitaire Nice
Nice, , France
CHU de Nimes
Nîmes, , France
Aphp - Bichat
Paris, , France
Aphp - Hegp
Paris, , France
APHP - Henri Mondor
Paris, , France
CHU Kremlin - Bicêtre
Paris, , France
Hôpital Saint Louis
Paris, , France
Hôpital Tenon
Paris, , France
Centre Hospitalier Universitaire Poitiers
Poitiers, , France
Centre Hospitalier Quimper
Quimper, , France
AUB Santé - Rennes
Rennes, , France
Centre Hospitalier Universitaire Rennes
Rennes, , France
Centre Hospitalier Universitaire Rouen
Rouen, , France
Centre Hospitalier Saint Brieuc
Saint-Brieuc, , France
Centre Hospitalier Universitaire Saint Etienne
Saint-Etienne, , France
Centre Hospitalier Saint-Nazaire
Saint-Nazaire, , France
Centre Hospitalier Alpes Léman
Sallanches, , France
Centre Hospitalier Saint-Malo
St-Malo, , France
Centre Hospitalier Universitaire Strasbourg
Strasbourg, , France
CHU Toulouse
Toulouse, , France
Clinique Saint Exupéry
Toulouse, , France
CHRU Bretonneau
Tours, , France
Centre Hospitalier Valenciennes
Valenciennes, , France
Centre Hospitalier Bretagne Atlantique
Vannes, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHD005-17
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.